is semaglutide off the fda shortage list GLP-1 Drugs: Removes from Drug Federal judge upholds FDA's removal

In 2025, 36% of employers offered to cover GLP-1 drugs as a treatment for both obesity and diabetes, with about 55% covering diabetes alone

Peptide therapy offers genuine benefits for properly selected candidates with appropriate protocols, but success requires informed decision-making and commitment to the process

The dual mechanism may offer a slight advantage for maintenance

To investigate the role of galectin-3 in the HGSOC tumor microenvironment, researchers examined its effects on the interaction between natural killer (NK) cells and neutrophils

At the dinner party, 26-year-old Yu Bai stood out with a distinctly different style

The reasons are likely multifactorialdisease complexity, bioavailability, formulation, dosing, and patient selection all matter